Home » Ligand Earns $1 Million Milestone Payment as GSK Begins Phase II Studies
Ligand Earns $1 Million Milestone Payment as GSK Begins Phase II Studies
Ligand Pharmaceuticals has earned a $1 million milestone payment from GlaxoSmithKline with that company's commencement of Phase II trials of SB-497115, an oral, small molecule drug that mimics the activity of thrombopoietin, a protein factor that promotes growth and production of blood platelets.
If the drug ultimately is approved and marketed, Ligand could receive double-digit royalties on product sales.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
11Jul
-
18Jul
-
21Oct